recommended reading

Study Points to Faster Acting Anthrax Vaccine

CDC

A new anthrax vaccine additive could help to guard people exposed to the lethal bacteria with fewer shots than a widely used formulation delivered in five doses over a year and a half, according to a new study made public on Friday.

Vaccine with the "CPG 7909" adjuvant prompted a stronger immune response in two doses than unaugmented treatment, according to the findings published in the journal Vaccine. Developers hope the research will yield a vaccine capable of conferring protection faster and in fewer injections to individuals exposed to anthrax, an agent long thought by experts to be a likely tool of bioterrorism.

The paper says scientists plan to further examine the additive's role in producing immune reactions and side effects, but it neither identifies a schedule for new research nor specifies whether the augmented vaccine might be administered outside "a post-exposure setting."

Each of four test groups received two "NuThrax" doses incorporating a different level of the experimental additive within the existing BioThrax vaccine. Additional subjects received either placebo shots or the standard version of BioThrax routinely administered to U.S. military personnel and held in the Strategic National Stockpile for general use in an anthrax outbreak.

Vaccinations incorporating any level of CPG 7909 produced stronger "toxin-neutralizing antibody responses" in two doses than vaccine without the adjuvant, but immune reactions evened out after four shots, according to the report. "Differences among the four [experimental vaccine] groups were not statistically significant," says an abstract of the report.

Immune responses from the augmented treatment reached their maximum after four weeks, seven days sooner than vaccine without the additive. However, recipients of the experimental vaccination also experienced temporary low counts of white blood cells involved in fighting infections, in part by helping to produce immune antibodies.

The "immunostimulatory" additive binds to a specific protein, setting off a chain reaction in the body's system for responding to disease threats.

The trial included 105 participants between 15 and 50 years old. No test subjects were exposed to anthrax in the study.

BioThrax manufacturer Emergent Biosolutions announced the start of a new phase 2 clinical study in January. The research team included experts from four other companies.

Threatwatch Alert

Thousands of cyber attacks occur each day

See the latest threats

JOIN THE DISCUSSION

Close [ x ] More from Nextgov
 
 

Thank you for subscribing to newsletters from Nextgov.com.
We think these reports might interest you:

  • Data-Centric Security vs. Database-Level Security

    Database-level encryption had its origins in the 1990s and early 2000s in response to very basic risks which largely revolved around the theft of servers, backup tapes and other physical-layer assets. As noted in Verizon’s 2014, Data Breach Investigations Report (DBIR)1, threats today are far more advanced and dangerous.

    Download
  • Featured Content from RSA Conference: Dissed by NIST

    Learn more about the latest draft of the U.S. National Institute of Standards and Technology guidance document on authentication and lifecycle management.

    Download
  • PIV- I And Multifactor Authentication: The Best Defense for Federal Government Contractors

    This white paper explores NIST SP 800-171 and why compliance is critical to federal government contractors, especially those that work with the Department of Defense, as well as how leveraging PIV-I credentialing with multifactor authentication can be used as a defense against cyberattacks

    Download
  • Toward A More Innovative Government

    This research study aims to understand how state and local leaders regard their agency’s innovation efforts and what they are doing to overcome the challenges they face in successfully implementing these efforts.

    Download
  • From Volume to Value: UK’s NHS Digital Provides U.S. Healthcare Agencies A Roadmap For Value-Based Payment Models

    The U.S. healthcare industry is rapidly moving away from traditional fee-for-service models and towards value-based purchasing that reimburses physicians for quality of care in place of frequency of care.

    Download
  • GBC Flash Poll: Is Your Agency Safe?

    Federal leaders weigh in on the state of information security

    Download

When you download a report, your information may be shared with the underwriters of that document.